<DOC>
	<DOCNO>NCT00443729</DOCNO>
	<brief_summary>The purpose study investigate efficacy , safety , tolerability investigational treatment patient Human Immunodeficiency Virus ( HIV ) .</brief_summary>
	<brief_title>MK0518 Treatment HIV-Infected Patients Switched From Protease Inhibitor Regimen ( 0518-033 ) ( TERMINATED )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Patient least 18 year age Patient human immunodeficiency virus ( HIV ) positive Patient document Human Immunodeficiency Virus ( HIV ) RiboNucleic Acid ( RNA ) &lt; 50 copies/milliliter ( mL ) least 3 month KALETRA base regimen Patient KALETRA base regimen least 3 month without change background antiretroviral therapy Patient documentation HIV RNA &gt; 50 copies/mL least 3 month KALETRA base regimen Patient plan become pregnant , nursing child Patient plan donate egg impregnate/donate sperm Patient receive Stavudine ( d4T ) component background antiretroviral therapy Patient currently receive second protease inhibitor addition KALETRA Patient currently receive , receive past twelve week , treatment management elevate lipid Patient use another experimental HIVintegrase inhibitor Patient current ( active ) diagnosis acute hepatitis due cause</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>treatment experience</keyword>
</DOC>